Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay

Similar documents
TB Intensive Tyler, Texas December 2-4, 2008

Tuberculosis Tools: A Clinical Update

Symptoms Latent TB Active TB

Technical Bulletin No. 172

TB Prevention Who and How to Screen

TB Intensive San Antonio, Texas November 11 14, 2014

TB Intensive Houston, Texas October 15-17, 2013

Identifying TB co-infection : new approaches?

TB Nurse Case Management San Antonio, Texas July 18 20, 2012

Didactic Series. Latent TB Infection in HIV Infection

MAIT cell function is modulated by PD-1 signaling in patients with active

Let s Talk TB A Series on Tuberculosis, A Disease That Affects Over 2 Million Indians Every Year

ESCMID Online Lecture Library. by author

Evaluation and Treatment of TB Contacts Tyler, Texas April 11, 2014

CHILDHOOD TUBERCULOSIS: NEW WRINKLES IN AN OLD DISEASE [FOR THE NON-TB EXPERT]

Targeted Testing and the Diagnosis of. Latent Tuberculosis. Infection and Tuberculosis Disease

Northwestern Polytechnic University

TB: Management in an era of multiple drug resistance. Bob Belknap M.D. Denver Public Health November 2012

Supplemental Figure 1. Gating strategies for flow cytometry and intracellular cytokinestaining

Targeted Tuberculin Testing and Treatment of Latent Tuberculosis Infection (LTBI) Lloyd Friedman, M.D. Milford Hospital Yale University

Barbara J Seaworth MD Medical Director, Heartland National TB Center Professor, Internal Medicine and Infectious Disease UT Health Northeast

Tuberculosis (TB) Fundamentals for School Nurses

New NICE guideline updates recommendations for diagnosing latent tuberculosis

Tuberculosis Facts. TB is not spread by: Sharing food and drink Shaking someone s hand Touching bed lines or toilet seats

Mycobacterial Infections: What the Primary Provider Should Know about Tuberculosis

TUBERCULOSIS. Presented By: Public Health Madison & Dane County

Principle of the FluoroSpot assay. Anti-tag mab-green. Streptavidin-Red. Detection mab-tag. Detection mab-biotin. Analyte. Analyte.

Mycobacterium tuberculosis

TUBERCULOSIS. Pathogenesis and Transmission

Tuberculosis What you need to know. James Zoretic M.D., M.P.H. Regions 2 and 3 Director

The Origin of Swine Flu

Using Interferon Gamma Release Assays for Diagnosis of TB Infection

Testing for TB. Bart Van Berckelaer Territory Manager Benelux. Subtitle

These recommendations will remain in effect until the national shortage of PPD solution has abated.

Didactic Series. Latent TB Infection in HIV Infection

Tuberculosis Update. Topics to be Addressed

Understanding and Managing Latent TB Infection Arnold, Missouri October 5, 2010

Making the Diagnosis of Tuberculosis

Approaches to LTBI Diagnosis

A Clinician s Perspective: Improving Rheumatology Patient Care Using the T-SPOT.TB Test

OSHA INSERVICE. Tuberculosis and Bloodborne Pathogens

The immunologic paradox in the diagnosis of

ORIGINAL ARTICLE. Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

Immunology of TB and its relevance to TB Control

QuantiFERON-TB Gold Plus

What you need to know about diagnosing and treating TB: a preventable, fatal disease. Bob Belknap M.D. Denver Public Health November 2014

Effect of prolonged incubation time on the results of the QuantiFERON TB Gold In-Tube assay for the diagnosis of latent tuberculosis infection

Testing for Tuberculosis Infection and Disease: The Expanding Role of Blood-based Assays

Latent Tuberculosis Infection (LTBI) Questions and Answers for Health Care Providers

TB IN EMERGENCIES. Disease Control in Humanitarian Emergencies (DCE)

Tuberculosis Infection in the US Military

Latent TB, TB and the Role of the Health Department

Tuberculosis. WRAIR- GEIS 'Operational Clinical Infectious Disease' Course UNCLASSIFIED

Diagnosis and Medical Management of TB Infection Lisa Y. Armitige, MD, PhD September 12, TB Nurse Case Management September 12 14, 2017

Diagnostic Value of ELISPOT Technique for Osteoarticular Tuberculosis

More significance of TB- IGRA except for the diagnose of tuberculosis

Monitoring tuberculosis progression using MRI and stereology

Monica Manandhar. 2 ND YEAR RESEARCH ELECTIVE RESIDENT S JOURNAL Volume V, A. Study Purpose and Rationale

Diagnosis and Medical Management of Latent TB Infection

PACKAGE INSERT. For In Vitro Diagnostic Use Only. This package insert covers use of:

Characteristics of Mycobacterium

Fundamentals of Tuberculosis (TB)

PREVENTION OF TUBERCULOSIS. Dr Amitesh Aggarwal

Tuberculosis Intensive

LTBI-Tuberculin skin test. T-Spot.TB Technology. QuantiFERON -TB Gold In Tube T-SPOT.TB ELISA ELISA

Review. Interferon- assays in the immunodiagnosis of tuberculosis: a systematic review. Interferon- assays for tuberculosis diagnosis

TB Intensive San Antonio, Texas

Latent Tuberculosis Best Practices

Conflict of Interest Disclosures:

Peggy Leslie-Smith, RN

Etiological Agent: Pulmonary Tuberculosis. Debra Mercer BSN, RN, RRT. Definition

RUTI: a new therapeutic vaccine to shorten the latent tuberculosis infection treatment

Tuberculosis and TNF Inhibitors

TB Intensive San Antonio, Texas. TB/HIV Co-Infection. Lisa Armitige, MD, PhD has the following disclosures to make:

Communicable Disease Control Manual Chapter 4: Tuberculosis

CHAPTER 3: DEFINITION OF TERMS

Latent Tuberculosis in Adults: From Testing TO Treatment

Shelley Rhodes & Martin Vordermeier

Variation in T-SPOT.TB spot interpretation between independent observers of different laboratories

The Challenges and Pitfalls in Diagnosing or Misdiagnosing Tuberculosis: Are the Days of TB Skin Tests Over?

TB Intensive San Antonio, Texas May 7-10, 2013

MYCOBACTERIUM. Mycobacterium Tuberculosis (Mtb) nontuberculous mycobacteria (NTM) Mycobacterium lepray

Contact Investigation and Prevention in the USA

HEALTH SERVICES POLICY & PROCEDURE MANUAL

P. Dandapat. Eastern Regional Station ICAR-Indian Veterinary Research Institute 37 Belgachia Road, Kolkata

Gary Reubenson 16 October 2012 PAEDIATRIC TUBERCULOSIS: AN OVERVIEW IN 40 MINUTES!!

Critical Evaluation of Tuberculosis Diagnostic Tests in Low- and High- Burden Settings

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Global Impact of TB

In our paper, we suggest that tuberculosis and sarcoidosis are two ends of the same spectrum. Given the pathophysiological and clinical link between

What the Primary Physician Should Know about Tuberculosis. Topics for Discussion. Life Cycle of M. tuberculosis

Preventing Tuberculosis (TB) Transmission in Ambulatory Surgery Centers. Heidi Behm, RN, MPH TB Controller HIV/STD/TB Program

Errors in Dx and Rx of TB

Diagnosis and Management of TB Disease Lisa Armitige, MD, PhD September 27, 2011

New Entrant Screening and Latent TB Get screened and find out if you have TB infection before you develop TB disease!

Clinical evaluation of QuantiFERON TB-2G test for immunocompromised patients

Latent tuberculosis infection

TB Update: March 2012

Tuberculosis in Children and Adolescents 2017

(b) Describe the role of antigen presentation in the body s specific immune response to infection by viruses. (4)

Tuberculosis in Children Jeffrey R. Starke, MD October 9, 2008

Transcription:

In the name of God

Evaluation of Mycobacterium tuberculosis specific T cell response to ESAT-6 and PPD antigen with ELISPOT assay presented by: M. Taheri

Symptoms of TB Cough for more than two week Bloody sputum fever decreased appetite Weight i loss sweating at night fatigue general weakness

Culture AFS (acid-fast stain ) Radiography TST in vivo Less specific PPD 2 patient visits results in 2-3 days inter-reader variability Diagnosis IFN-γ γ measurement based method in vitro TB specific antigens 1 patient visit results possible in 1 day unknown variability

Materials & Mthd Methods

weight loss Cough The first group (patients individuals) id bloody sputum night g sweating AFS positive

3 patients (14 female and 16 mal) with mean age 33 years 2 percent (Afghanistan) Culture (all positive) Antibiogram test results (all isolates against first- line TB treatment t t drugs are sensitive ) (Pyrazynamayd, Ethambutol, rifampin, streptomycin and isoniazid) PCR (all isolation positive)

The second group (people treated) Drug regimen (Isoniazid, Streptomycin, Ethambutol, and Rifampin) to 6 months had received AFS negative 19 individual (12 males and 7 females) with mean age 31 years 2 percent (Afghanistan) AFS (negative in all these people)

The third group (people suspected) Sputum test negative after three times 22 patients (12 males and 1 females) with mean age 35 years 1 %( Afghanistan) TST (5% positive)

The fourth group (Normal) 22 individuals (12 women and 1 men) with The mean age of this group 24/5 years All received the BCG vaccine no clinical symptoms were related to tuberculosis TST (negative in all these people)

samples transferring (four groups) TST Blood cell separation by Ficoll gradient method

sampling T-SPOT SPOT.TBTB PBMC Centrifugation Overnight culture in presence of ESAT-6 and PPD anti- IFN-γ antibodies; + and - Controls Optic reading

Elispot Kit activation by ethanol 7 percent Adding the coating antibody (first antibody) Adding the Blocking buffer Adding the cell with antigen Washing Adding the Biotinylated detection antibody (secondary antibody) Washing GABA (φ-labeled anti-biotin antibodies) Ati Activatorst

ELISPOT Nil Control Infection Positive Control Oxford Immunotec

Results

A. Negative control B. Positive control C. Sample

spot number in Patients and Healed group 5 Spot in Patient group 5 Spot in Healing group r pot Numbe S 25 Sp pot Number 25 PPD Esat 6 Type of Ag PPD Type of Ag Esat6 ESAT_6: Patient group: 11.23 ± 2.3 ESAT_6: Healed group : 12 ± 3.4 PPD: Patient group: 7.43 ± 1.5 PPD: Healed group : 7.75 ± 1.5

Spot number in suspicious and Normal groups 3 Spot in Suspicious group 3 Spot in Normal group Spot Number 2 1 Spot Number 2 1 PPD Esat6 PPD Esat6 Type of Ag Type of Ag ESAT-6: 3.63 ±1.65 PPD: 2.42 ± 1.12 ESAT-6: PPD:1.27 ±.79

Spot number of PPD antigen stimulated in different groups 4 Number Spot 3 2 1 Patient Healing Suspicies s Norm al Suspected and the patient groups (P<.1) Patients and normal groups (P<.1) Treatment and normal (P<.1) 1) patient and treated groups (P=1) Suspected and normal (P<.526)

Analysis of spots stimulates Esat-6 antigen in different groups 6 5 Sp pot Number 4 3 2 1 Patient Healing Suspicies Normal Suspected and the patient groups (P<.1) Patients and normal groups (P<.1) patient and treated groups (P=1) Suspected and normal (P=.4)

IFN-γ production rate in different groups by ELISA method Results at a minimum, maximum, standard error and mean IFN-γ secretory study groups in medium by ELISA method Suspected and the patients groups (P<.18) Patients and normal groups (P<.3) patients and treated groups (P<.95) Suspected and treated t (P=.136) Suspected and normal (P=.944) ation (pg/ml) IFN II concentr I 25 15 5 15 1 5 PHA nt t suspicious s Patient Healed patient without PHA Normal groups patient Treatm ent Suspec ted normal No. 3 19 22 22 Mean 47.12 39.79 7.58 SE 12.3 12.8 3.7 Min Max 2 178.3 82.17

Discussioni

IFN-γ As a marker for activated lymphocytes Use ESAT-6 antigens in the Use PPD antigens in the Elispot test: Elispot test: Patients and treated groups: All positive Patients and treated groups: All positive Normal group: All negative Normal group: 27.3% positive! Suspected group : 27.3% positive! False positive and Negative

Thus, results of measurement of IFN-γ secretion by lymphocytes stimulating environment with ESAT-6 to the ELISA test results to confirm the ELISPOT test. patients and treated groups: positive the Normal groups: Negative 4 patients Negative No significant differences between normal and suspected whit ELISA While ELISPOT test overlapping between TST and Elispot test about 53% While in our study 25%...

Flow Cytometry Real Time PCR Role of IFN-γ γ in host immunity against TB, activating macrophages to induced Cytokines such as the: Inducible Protein1 (IP-1) Monocyte Chemo attractant Protein 2 (MCP-2) Monokine induced by IFN-gamma (MIG) Dual staining ELISPOT method

Thanks for your attention